CSF immunophenotyping by FACS CSF cell population identification by antigens expressed by the cells, detected by specific antibodies. Outcome Exploratory CSF kappa Quantitative measure of kappa free light chains in CSF. Outcome Exploratory CSF myelin basic protein (MBP) Quantitative measure of detectable MBP like material in CSF. Outcome Exploratory CSF neural cell adhesion molecule (NCAM) Measured in ng/mL. Quantitative measure of soluble NCAM in CSF. Outcome Exploratory CSF neurofilament light chains Intentionally left blank Outcome Exploratory CSF NMO IgG IgG antibodies reacting to aquaporin 4. Biomarker for NMO Devic spectrum disorder. Outcome Exploratory Tears OCB Qualitative detection of two or more IgG electrophoretic bands in tears but not blood. Outcome Exploratory Table for CSF Culture CDE General Comments Purpose Classification Bacterial, Fungal culture Cryptococcus neoformans antigen; Mycobacteria culture. Culture of CSF to identify presence of a bacterial or fungal pathogen. Diagnosis/ Safety Supplemental Sterile fluid culture Gram stain. No identification/growth of any microbial pathogen from CSF cultures. Diagnosis/ Safety Supplemental Table for Blood Tests CDE General Comments Purpose Classification Pregnancy test, blood Test for beta subunit of human chorionic gonadotropin; results reported as positive, negative or not done; sensitive to as low as 1mIU/ml serum Safety Core
5, 10 Methylene Tetra Hydrofolate Reductase Results reported as positive, negative or not done. Measure of enzyme which metabolizes homocysteine. Diagnosis/ Safety Supplemental Activated Partial Thromboplastin Time (aPTT) Measured in seconds. Detects abnormalities in blood clotting and anti- coagulants. Diagnosis/ Safety Supplemental Activated Protein C Resistance Results reported as positive, negative or not done. Disorder characterized by poor anticoagulant response to activated protein C; acquired or inherited. Diagnosis Supplemental Ammonia Results reported as positive, negative or not done. Quantitative ammonia level. Safety Supplemental Anti-CardiolipinAb, IgG, IgM Results reported as positive, negative or not done; measured in U/mL Diagnosis Supplemental Anti-ds DNA Ab Results reported as positive, negative or not done; measured in U/mL Diagnosis/ Safety Supplemental Anti-ENA/ ANA Screen Results reported as positive, negative or not done; measured in U/mL Diagnosis/ Safety Supplemental Anti-HAV Hepatitis Results reported as positive, negative or not done; measured in U/mL Diagnosis/ Safety Supplemental Anti-HCA Hepatitis Results reported as positive, negative or not done; measured in U/mL Safety Supplemental Anti-HCB Hepatitis Results reported as positive, negative or not done; measured in U/mL Safety Supplemental Anti-HCV Hepatitis Results reported as positive, negative or not done; measured in U/mL Diagnosis Supplemental Anti-HIV Ab Antibodies to HIV-1 and HIV-2, usually by ELISA; results reported as positive, negative or not done; positive result should be confirmed by Western Blot Diagnosis/ Safety Supplemental
Anti-HIV ½ Ab Results reported as positive, negative or not done; measured in U/mL Diagnosis/ Safety Supplemental Anti-HLTV-I Ab Results reported as positive, negative or not done; measured in U/mL Diagnosis Supplemental Anti-Interferon Ab Binding Results reported as positive, negative or not done; measured in U/mL. Diagnosis/ Safety Supplemental Anti-Interferon Ab Neutralizing Results reported as positive, negative or not done; measured in U/mL; Sample titers, or ranges: negative (<1:20); moderate positive (>1:20 to <1:100) and highly positive (>1:100). Diagnosis/ Safety Supplemental Anti-JC VAb (virus antibodies) Results reported as positive, negative or not done; measured in U/mL Diagnosis/ Safety Supplemental Anti-microsomal Ab Results reported as positive, negative or not done; measured in U/mL Diagnosis/ Safety Supplemental Anti-mycoplasma Ab Results reported as positive, negative or not done; measured in U/mL Diagnosis/ Safety Supplemental AntiNeutrophil Cytoplasmic Antibodies Results reported as positive, negative or not done Diagnosis/ Safety Supplemental Anti-nuclear Ab Results reported as positive, negative or not done; measured in titer Diagnosis Supplemental Anti-SSA Results reported as positive, negative or not done; measured in U/mL Diagnosis/ Safety Supplemental Anti-SSB Results reported as positive, negative or not done; measured in U/mL Diagnosis/ Safety Supplemental Antithrombin Activity (AT-III) Results reported as positive, negative or not done; measured in U/mL Diagnosis/ Safety Supplemental Anti-thyroglobulin Ab Results reported as positive, negative or not done; measured in U/mL Diagnosis/ Safety Supplemental Anti-thyroid Ab Some laboratories report as anti-thyroid peroxidase Diagnosis/ Safety Supplemental Anti-VZV Ab Results reported as positive, negative or not done; measured in U/mL Diagnosis/ Safety Supplemental Arterial Blood Gases Measured in mmHg Safety Supplemental
β 2- glycoprotein Ab IgG, IgM Measured in SGU and SMU, respectively Diagnosis Supplemental Ceruloplasmin Measured in mg/dL Diagnosis/ Other Supplemental Cholesterol - HDL*** Measured in mg/dL (U.S.) or mmol/L (outside U.S.) Safety Supplemental Cholesterol - LDL*** Measured in mg/dL (U.S.) or mmol/L (outside U.S.) Safety Supplemental Cholesterol, total Measured in mg/dL (U.S.) or mmol/L (outside U.S.) Safety Supplemental Cholesterol - VLDL Measured in mg/dL (U.S.) or mmol/L (outside U.S.) Safety Supplemental C-reactive protein (CRP) Measured in mg/L Diagnosis Supplemental Creatinine Clearance Measured in mL/min Safety Supplemental Creatine Kinase - Myocardial Bands Measured in ng/mL Safety Supplemental D-dimer Results reported as positive, negative or not done Safety Supplemental Epstein-Barr virus (EBV) panel Includes early antigen (EA), VCA IgG, IgM, and EBNA. Results reported as positive, negative or not done. Diagnosis/ Other Supplemental Erythrocyte Sedimentation Rate Measured in mm/hr Diagnosis Supplemental Factor V Leiden Mutation Results reported as negative, heterozygous, or homozygous Diagnosis Supplemental Fibrinogen Measured in mg/dL Safety Supplemental Folate, serum level Measured in ng/mL Diagnosis Supplemental GAD 65 Ab Intentionally left blank Intentionally left blank Intentionally left blank Glomerular Filtration Rate (eGFR) Sample ranges: estimated creatinine clearance – normal 90+; mild 60-89; moderate 30-59; <15ml/min = kidney failure; measured in mL/min; required if study uses MRI with contrast Safety Supplemental Glycosylated hemoglobin (HbA1c) Results indicate "average" blood sugar over 6-12 week time; sample normal is 4%-6%; measured in % Diagnosis Supplemental High sensitivity C Reactive Protein Acute phase reactant elevated with inflammation; non-specific; not clear, usually is <10.0; measured in mg/L Diagnosis Supplemental
HLA-A, B, Cw Genetic alleles within human MHC locus alleles, e.g. HLA-A*0101, etc. Other Supplemental HLA-DR, DQ Genetic alleles within human MHC locus alleles, e.g. HLA-DRB1*1501, etc. Other Supplemental Homocysteine Elevated levels associated with B12, folic acid, and pyridoxine deficiencies; sample elevated level is > 10.4 μmol/L, or > 140 μg/dl; measured in μmol/L or ug/dL Diagnosis Supplemental Human T-cell lymphotropic virus type 1 (HTLV-1) Antibodies to retrovirus HTLV-1, typically screen with ELISA, confirmation with Western blot positive, negative, sometimes provides titers Diagnosis Supplemental Human T-cell lymphotropic virus type 2 (HTLV-2) Antibodies to retrovirus HTLV-2, positive, negative, sometimes provides titers Diagnosis Supplemental Lupus Anticoagulant Functional test detects immunoglobulin that binds phospholipids, name is misnomer, functionally Pro-thrombotic; results reported as positive, negative or not done Diagnosis Supplemental Lyme disease Ab, Serum Antiboodies to Borrelia Burgdorferi, screen with ELISA, confirmation with Western blot; results reported as positive, indeterminant/borderline, negative or not done Diagnosis Supplemental Methylmalonic acid Elevated levels associated with B12 deficiency; sample normal range nmol/L; often elevated non-specifically in elderly; measured in nmol/L Diagnosis Supplemental
Prothrombin gene mutation Prothrombin 20210 genetic point mutation predisposes to clotting negative, heterozygous, homozygous Diagnosis Supplemental Prothrombin time/ international normalized ratio (PT/INR) Ratio of PT tested to PT of normal controls, used to standardize PT sample normal range is 0.8-1.2; measured as a ratio Safety Supplemental Protoplasmic-staining AntiNeutrophil Cytoplasmic Antibodies (ANCA) Autoantibodies to cytoplasmic antigens in neutrophils; positive in several types of vasculidites, e.g. Wegner's, Churg-Strauss; usually given as titers Diagnosis Supplemental Rapid plasma reagin (RPR/VDRL) Screening test for antibodies to syphilis in blood; most sensitive in Secondary Syphilis, less sensitive in primary and tertiary syphilis; should be confirmed with the more specific FTA-ABS test Diagnosis Supplemental Rheumatoid factor IgM autoantibody against Fc portion of self IgG; can bind to IG to form immune complexes; positive in 80% of patients with Rheumatoid Arthritis, 70% of patients with Sjogren's Syndrome, in 5-10% healthy controls Diagnosis Supplemental serum IgA Isotype of Ig; sample normal range is 70-370 measured in mg/dL Other Supplemental serum IgE Isotype of Ig; upper limit of normal not well defined; measured in mg/dL Other Supplemental serum IgG Isotype of Ig; sample normal range is 700-1450; measured in mg/dL Other Supplemental serum IgM Isotype of Ig; sample normal range is 30-210; measured in mg/dL Other Supplemental